Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Voriconazole
Drug ID BADD_D02369
Description Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections.[L15571] It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha sterol demethylase makes it useful against some [fluconazole]-resistant organisms.[A236050] Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002.[L34660]
Indications and Usage For the treatment of esophageal candidiasis, cadidemia, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.[L9821, L15571]
Marketing Status approved
ATC Code J02AC03
DrugBank ID DB00582
KEGG ID D00578
MeSH ID D065819
PubChem ID 71616
TTD Drug ID D0N3VR
NDC Product Code 0781-5667; 60715-1700; 65372-1175; 27241-063; 39822-1077; 43386-088; 0378-1640; 66039-951; 70966-0030; 47781-466; 0049-4190; 55111-099; 58032-2007; 66039-876; 43386-038; 51079-164; 0049-3190; 64980-274; 64980-275; 65862-891; 68462-572; 70594-067; 70710-1247; 60687-273; 0378-1626; 65841-830; 72572-875; 68554-0111; 75945-102; 16714-199; 43547-378; 59762-0936; 63739-008; 65162-913; 65841-831; 0904-6596; 65862-916; 71052-149; 40032-038; 43386-089; 50268-803; 0049-3180; 68083-321; 71288-027; 72578-062; 14501-0014; 52562-001; 27241-062; 43547-377; 51552-1524; 16714-198; 59762-0934; 60687-294; 65219-190; 65862-892; 70771-1413; 72843-441; 0781-5668; 63126-911; 0049-3170; 70436-029; 72578-063; 0781-3416; 0904-7024; 51552-1573; 53296-0081; 64220-140; 65015-801; 73223-005; 51079-165; 63629-8734; 0049-3160; 68462-573; 72266-131; 51407-133; 55150-321; 59762-0935
UNII JFU09I87TR
Synonyms Voriconazole | UK 109,496 | UK-109,496 | UK109,496 | UK-109496 | UK109496 | UK 109496 | Vfend
Chemical Information
Molecular Formula C16H14F3N5O
CAS Registry Number 188416-29-7
SMILES CC(C1=NC=NC=C1F)C(CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abnormal dreams17.15.02.001; 19.02.03.0010.028462%-
Accommodation disorder06.02.04.001---
Actinic keratosis23.01.06.0010.111524%-
Acute hepatic failure09.01.03.0010.037755%-
Acute leukaemia01.10.02.001; 16.01.02.0010.008713%-
Acute lymphocytic leukaemia01.10.01.001; 16.01.01.0010.017426%-
Acute myeloid leukaemia01.10.05.001; 16.01.05.0010.072606%-
Acute respiratory distress syndrome10.02.01.067; 22.01.03.001; 24.03.02.0340.011617%
Adrenal insufficiency05.01.02.001; 14.11.01.0040.008713%
Ageusia07.14.03.003; 17.02.07.001---
Agitation17.02.05.012; 19.06.02.0010.073768%
Agranulocytosis01.02.03.0010.059247%-
Akathisia17.01.02.002; 19.06.02.006--
Alanine aminotransferase increased13.03.04.005--
Albuminuria20.02.01.001---
Alopecia23.02.02.001--
Altered state of consciousness17.02.04.001; 19.07.01.0030.113266%-
Amaurosis06.02.10.0010.005809%-
Amnesia17.03.02.001; 19.20.01.001--
Anaemia01.03.02.001--
Anaemia macrocytic01.03.02.002; 14.12.01.002---
Anaemia megaloblastic01.03.02.003; 14.12.01.003---
Anaphylactic shock10.01.07.002; 24.06.02.004---
Anaphylactoid reaction10.01.07.003; 24.06.03.007---
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Anorectal disorder07.03.01.001---
Anuria20.01.03.0020.005809%-
Anxiety19.06.02.002--
The 1th Page    1 2 3 4 5    Next   Last    Total 21 Pages